Patents by Inventor Tamar R. Grossman
Tamar R. Grossman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926830Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: GrantFiled: September 2, 2021Date of Patent: March 12, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: Tamar R. Grossman, Michael L McCaleb, Andrew T. Watt, Susan M. Freier
-
Publication number: 20230357776Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: ApplicationFiled: May 19, 2023Publication date: November 9, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
-
Patent number: 11732265Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: GrantFiled: May 7, 2021Date of Patent: August 22, 2023Assignee: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
-
Patent number: 11713462Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: GrantFiled: December 23, 2021Date of Patent: August 1, 2023Assignees: Ionis Pharmaceuticals, Inc., The Hospital for Sick ChildrenInventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
Publication number: 20230057718Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: ApplicationFiled: May 7, 2021Publication date: February 23, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
-
Publication number: 20220243209Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: ApplicationFiled: September 2, 2021Publication date: August 4, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
-
Publication number: 20220112502Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: ApplicationFiled: December 23, 2021Publication date: April 14, 2022Inventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
Patent number: 11236339Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: GrantFiled: June 19, 2017Date of Patent: February 1, 2022Assignees: Ionis Pharmaceuticals, Inc., The Hospital for Sick ChildrenInventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
Patent number: 11197884Abstract: Provided herein are methods, compounds, and compositions for modulating expression of at least one member of the Notch signaling pathway in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a respiratory disorder associated with excessive mucus production in an individual.Type: GrantFiled: August 17, 2018Date of Patent: December 14, 2021Assignee: Ionis Pharmaceuticals, Inc.Inventor: Tamar R. Grossman
-
Publication number: 20200171071Abstract: Provided herein are methods, compounds, and compositions for modulating expression of at least one member of the Notch signaling pathway in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a respiratory disorder associated with excessive mucus production in an individual.Type: ApplicationFiled: August 17, 2018Publication date: June 4, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventor: Tamar R. Grossman
-
Publication number: 20200149047Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: ApplicationFiled: June 12, 2019Publication date: May 14, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
-
Publication number: 20200048638Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: ApplicationFiled: March 18, 2019Publication date: February 13, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
-
Publication number: 20190194666Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: ApplicationFiled: June 19, 2017Publication date: June 27, 2019Applicants: Ionis Pharmaceuticals, Inc., The Hospital for Sick ChlidrenInventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
Patent number: 10280423Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: GrantFiled: May 1, 2015Date of Patent: May 7, 2019Assignee: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Susan M. Freier
-
Publication number: 20190048351Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: ApplicationFiled: March 5, 2018Publication date: February 14, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
-
Publication number: 20170159055Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: ApplicationFiled: May 1, 2015Publication date: June 8, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
-
Publication number: 20160222389Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: ApplicationFiled: September 12, 2014Publication date: August 4, 2016Applicant: Ionis Pharmaceuticals, Inc.Inventors: Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
